Motor Neuron Disease Population-Based Registry in Egypt: Where Do We Stand?
- PMID: 38870925
- DOI: 10.1159/000539468
Motor Neuron Disease Population-Based Registry in Egypt: Where Do We Stand?
Abstract
Background: There is a growing body of evidence indicating that the worldwide distribution of amyotrophic lateral sclerosis (ALS) is far from uniform. This is evident through variations in the epidemiology, genetics, and phenotypical characteristics of ALS and other motor neuron diseases (MND) across different regions. However, comprehensive ALS epidemiological studies are still lacking in many parts of the world, especially in Africa. Therefore, we propose the establishment of a population-based register for ALS/MND in Egypt, an important part of Africa with a population of more than 100 millions of people.
Summary: Given Egypt's distinctive social and demographic characteristics, it is highly recommended to employ specific, recently developed epidemiological techniques for assessing the prevalence and incidence of these diseases within the country. By utilizing these methods, we can gather invaluable data that will contribute to a deeper understanding of ALS and enable us to effectively address its impact on the population of Egypt.
Key messages: Our goal with this pioneering ALS/MND population-based register in Egypt is to define the burden of ALS in this part of Africa and to increase the chances for this consanguineous population to get access to modern individualized genetic therapies. Additionally, we aspire to uncover potential environmental factors and gene-environment interactions that contribute to the development of ALS. This knowledge of MND individual and group risk in Egypt will not only open doors for interventions but also provide opportunities for future research and discovery.
Keywords: Africa; Amyotrophic lateral sclerosis; Egypt; Motor neuron diseases; Registry.
© 2024 S. Karger AG, Basel.
Similar articles
-
Estimating Amyotrophic Lateral Sclerosis and Motor Neuron Disease Prevalence in Portugal Using a Pharmaco-Epidemiological Approach and a Bayesian Multiparameter Evidence Synthesis Model.Neuroepidemiology. 2019;53(1-2):73-83. doi: 10.1159/000499485. Epub 2019 May 22. Neuroepidemiology. 2019. PMID: 31117082
-
Amyotrophic Lateral Sclerosis Descriptive Epidemiology: The Origin of Geographic Difference.Neuroepidemiology. 2019;52(1-2):93-103. doi: 10.1159/000493386. Epub 2019 Jan 2. Neuroepidemiology. 2019. PMID: 30602169 Review.
-
Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease.Cochrane Database Syst Rev. 2019 Dec 19;12(12):CD011742. doi: 10.1002/14651858.CD011742.pub3. Cochrane Database Syst Rev. 2019. PMID: 31853962 Free PMC article.
-
Estimation of the prevalence and incidence of motor neuron diseases in two Spanish regions: Catalonia and Valencia.Sci Rep. 2021 Mar 18;11(1):6207. doi: 10.1038/s41598-021-85395-z. Sci Rep. 2021. PMID: 33737526 Free PMC article.
-
The challenge of amyotrophic lateral sclerosis descriptive epidemiology: to estimate low incidence rates across complex phenotypes in different geographic areas.Curr Opin Neurol. 2022 Oct 1;35(5):678-685. doi: 10.1097/WCO.0000000000001097. Epub 2022 Aug 17. Curr Opin Neurol. 2022. PMID: 35946801 Free PMC article. Review.
Cited by
-
Analysis of Mortality Causes and Locations in Veterans with ALS: A Decade Review.Med Sci Monit. 2024 Nov 17;30:e945816. doi: 10.12659/MSM.945816. Med Sci Monit. 2024. PMID: 39550606 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous